Compare Equinor ASA (EQNR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Tempus AI — how do they compare? Equinor ASA trades at $42.85 (market cap $100.03B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Equinor ASA is far larger — about 7.8× Tempus AI's market cap, and Equinor ASA pays a 3.75% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Tempus AI for 22 Days on average.
| EQNR | TEM | |
|---|---|---|
Market Cap | $100.03B | $12.77B |
Volume | 4,457,638 | 8,980,490 |
Sector | Energy | Broad Market / Factor |
52-Week High | $45.75 | $99.28 |
52-Week Low | $22.41 | $41.55 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $108.72B | $13.40B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $42.93, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The stock presents compelling value with a P/E of 11.28 and EV/EBITDA of 2.35, well below industry averages. Recent developments include expansion in LNG operations and carbon capture projects, while maintaining strong operational cash flow of $20B. The company continues shareholder returns through dividends and buybacks.
EQNR offers significant upside potential with a consensus price target of $70.50 representing 64% upside, supported by improving earnings outlook and strategic LNG expansion. Key risks include volatile energy prices and execution challenges in new projects. Analyst sentiment is mixed with 30% buy ratings, but recent Zacks upgrades to Strong Buy highlight growing optimism about earnings recovery through 2026.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
